Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) CEO Christopher Moreau presents at Proactive's One2One virtual investor forum.
Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets.
Most recently, Algernon Pharmaceuticals signed a deal with lab services firm Charles River Laboratories for pre-clinical research studies on the psychedelic compound DMT to treat strokes.